RPS29A Antibody

What is RPS29 and what are its key characteristics relevant to antibody-based detection?

RPS29 (Ribosomal Protein S29) is a small protein component of the 40S ribosomal subunit belonging to the S14P family of ribosomal proteins. For antibody-based detection, researchers should note:

• Molecular characteristics: 56 amino acids, approximately 7 kDa molecular weight

• Contains a distinctive C2-C2 zinc finger-like domain that binds zinc

• Primarily localized in the cytoplasm and endoplasmic reticulum

• Highly conserved across species with identical sequences in many mammals

• Functions as a component of the small ribosomal subunit and is essential for rRNA processing and ribosome biogenesis

When designing experiments using RPS29 antibodies, consider that this protein enhances tumor suppressor activity of Ras-related protein 1A (KREV1) and its expression is widespread across most tissue types .

To maintain antibody activity, proper storage and handling protocols are crucial:

For optimal performance: Allow antibodies to equilibrate to room temperature before opening. Centrifuge briefly before use to collect solution at the bottom of the vial. Avoid repeated freeze-thaw cycles as they can degrade antibody quality .

What controls should be included when using RPS29 antibodies in experimental designs?

Robust experimental design requires appropriate controls:

• Positive controls:

  • Cell lines: HeLa cells, HepG2 cells, Jurkat cells have been validated

  • Tissues: Mouse brain tissue, human pancreas demonstrate positive reactivity

• Negative controls:

  • Primary antibody omission

  • Isotype-matched irrelevant antibody at the same concentration

  • RPS29 knockout/knockdown cells (if available)

• Technical validation controls:

  • For Western blot: Loading controls (β-actin, tubulin)

  • For immunoprecipitation: IgG control pull-down

  • For IHC/ICC: Peptide competition assay to confirm specificity

Methodological recommendation: When validating a new RPS29 antibody lot, compare protein expression levels and patterns with previously validated lots to ensure consistency before proceeding with critical experiments .

How can researchers troubleshoot inconsistent results when using RPS29 antibodies in different experimental systems?

When facing inconsistent results, systematically evaluate these factors:

• Antibody reliability assessment:

  • Studies show that antibody reliability significantly influences observed mRNA-protein correlations in tumor cohorts

  • Validate antibody specificity through Western blot (single band at ~7kDa) and correlation between RPPA and Western blot measurements (Pearson correlation >0.7)

• Sample preparation issues:

  • For cellular fractionation experiments: RPS29 is primarily cytoplasmic; inadequate lysis may reduce detection

  • For fixed samples: Over-fixation can mask epitopes; optimize fixation time and antigen retrieval methods

  • For detection of protein interactions: Native conditions may be required to preserve binding sites

• Protocol optimization strategy:

  • Systematically vary antibody concentration, incubation time, temperature, and blocking reagents

  • Document each parameter change and resulting signal-to-noise ratio

  • For Western blots, try reducing agents or DTT concentrations if the zinc finger domain is involved in antibody recognition

Methodological recommendation: Create a troubleshooting matrix documenting all experimental variables (sample preparation method, buffer composition, antibody concentration, incubation conditions) to systematically identify the source of inconsistency .

What methodologies are effective for studying RPS29's role in ribosome biogenesis and Diamond-Blackfan anemia?

Diamond-Blackfan anemia (DBA) research involving RPS29 requires specialized approaches:

• Genetic analysis workflow:

  • Whole-exome sequencing identified pathogenic RPS29 mutations (p.I31F and p.I50T) in DBA patients

  • Both mutations are amino acid substitutions in exon 2 and resulted in haploinsufficiency of RPS29 expression

• Functional validation techniques:

  • Pre-ribosomal RNA (rRNA) processing analysis: Compare processing defects between DBA patient samples and healthy controls

  • Zebra fish DBA model: Use rps29(-/-) mutant zebra fish to test rescue capability of wild-type versus mutant RPS29

• Molecular mechanism investigation:

  • RPS29 antibodies can be used to quantify protein expression levels in patient-derived cells

  • Immunofluorescence to examine subcellular localization alterations in mutant cells

  • Co-immunoprecipitation to assess altered protein-protein interactions due to mutations

Methodological approach: When studying RPS29 mutations in DBA, combine genetic sequencing with functional assays in multiple systems (cell lines, zebra fish models) to establish causality and mechanism .

How can RPS29 antibodies be effectively utilized in protein-protein interaction studies?

For studying RPS29 protein interactions:

• Tandem affinity purification (TAP) methodology:

  • The TAP tag should comprise two IgG binding domains (streptavidin and calmodulin binding peptide) separated by a TEV protease cleavage site

  • N-terminally TAP-tagged RPS29 can be stably expressed in appropriate cell lines (e.g., C6/36 cells)

  • Verification of expression should be performed by Western blot using anti-His antibody

  • Following purification, analyze products by SDS-PAGE and silver staining before mass spectrometry identification

• GST pull-down protocol optimization:

  • Clone RPS29 into the pGEX-6p-1 expression vector downstream of the GST sequence

  • Clone interacting protein candidates into the PET-32a expression vector with His tag

  • Verify interactions in vitro using purified proteins and in vivo through co-immunoprecipitation

  • Confirm localization patterns through immunofluorescence

• Visualization of interaction dynamics:

  • Use tags such as GFP-RPS29 and RFP-interacting protein to visualize co-localization in living cells

  • Confirm biological relevance through functional assays specific to the interacting protein's function

This approach successfully identified CYP6N3 as an RPS29-interacting protein, demonstrating that RPS29 increases CYP6N3 protein degradation through the proteasome pathway .

What are the latest advancements in antibody technology applied to RPS29 research?

Recent technological innovations are enhancing RPS29 antibody applications:

• Advanced antibody engineering approaches:

  • Humanization of antibodies through variable domain resurfacing based on 3D structure of Fv fragments

  • Framework region modifications to restore binding affinity in humanized antibodies (as demonstrated with other antibodies)

  • Development of antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)

• RNA-protein interaction analysis at chromatin targets:

  • RT&Tag methodology allows chromatin-associated RNA profiling using antibody-targeted approaches

  • This technique isolates nuclei bound to paramagnetic beads followed by antibody binding and reverse transcription with tagmentation

• Active learning for improving out-of-distribution predictions:

  • Novel active learning strategies for antibody-antigen binding prediction in library-on-library settings

  • These approaches can reduce the number of required antigen mutant variants by up to 35%

  • Simulation frameworks like Absolut! can be used to evaluate out-of-distribution performance

Methodological implication: Researchers should consider these emerging technologies when designing experiments requiring highly specific detection or studying RPS29's role in complex cellular contexts .

How can researchers ensure reproducibility when using different RPS29 antibody products across studies?

Ensuring reproducibility requires systematic validation and documentation:

• Comprehensive antibody validation strategy:

  • Validate each antibody using multiple techniques (Western blot, IP, IHC, IF)

  • Document epitope information and compare across antibodies (N-terminal vs. C-terminal targeting)

  • Compare antibody performance using known positive controls (e.g., Jurkat cell lysate)

• Standardized reporting framework:

  Parameter	Required Documentation	Example
  Antibody identifiers	Catalog #, RRID, lot #	RRID:AB_2180751, Cat# 17374-1-AP
  Validation data	Images of blots, IHC slides	See validation gallery on manufacturer site
  Epitope information	Amino acid sequence	MGHQQLYWSHPRKFGQGSRSCRVCSNRHGLIRKYGLNMCRQCFRQYAKDIGFIKL
  Experimental conditions	Buffer composition, incubation parameters	PBS w/0.02% sodium azide, 50% glycerol pH 7.3

• Correlation with orthogonal methods:

  • Compare antibody-based detection with mass spectrometry quantification

  • Analyze mRNA-protein correlations to assess technical vs. biological variability

  • Document Pearson correlation values between different measurement techniques (>0.7 considered reliable)

Methodological recommendation: Maintain a laboratory database of antibody validation data and establish minimum quality thresholds before using antibodies in critical experiments. When reproducibility issues arise between studies, evaluate antibody validation status as a potential contributing factor .

What are the protocols for using RPS29 antibodies in studying metabolic insecticide resistance?

Research has identified a novel role for RPS29 in regulating metabolic insecticide resistance through interaction with CYP6N3:

• Experimental setup for CYP6N3-RPS29 interaction studies:

  • Cell culture: Maintain C6/36 cells in DMEM with 10% FBS at 28°C in 5% CO₂

  • Vector construction: Insert RPS29 and appropriate tags (GFP, GST) into expression vectors

  • Transfection: Optimize for cell type following manufacturer's protocols

• Validation methodology:

  • Confirm protein expression by Western blot using relevant antibodies (anti-GST, -HIS, -GFP, -MYC)

  • Use horseradish peroxidase-conjugated secondary antibodies and ECL detection

  • Quantify gene expression via RT-PCR using β-actin as internal control

• Functional assessment protocol:

  • CCK-8 viability assay to study deltamethrin (DM) resistance

  • Overexpress CYP6N3 to confirm enhanced DM resistance

  • Co-express RPS29 to demonstrate reversal of resistance

  • Analyze protein degradation mechanisms using proteasome inhibitors

This systematic approach revealed that RPS29 regulates insecticide resistance by promoting CYP6N3 degradation through the proteasome pathway, suggesting potential applications in pest management strategies .

How can RPS29 antibodies be optimized for multiplex immunoassays and high-throughput screening?

For multiplex and high-throughput applications:

• ELISA kit optimization considerations:

  • Detection range: Commercial RPS29 ELISA kits typically offer 100-2500 pg/mL range

  • Minimum detection limit: Approximately 100 pg/mL with sensitivity of 1.0 pg/mL

  • Sample compatibility: Cell culture supernatant, plasma, serum, tissue homogenate

• Protocol adaptation for high-throughput screening:

  • Use 96-well stripwell microtiter plates for flexibility in sample numbers

  • Employ competition ELISA format for quantitative analysis

  • Prepare necessary controls and standards according to manufacturer guidelines

• Equipment requirements:

  • Precision pipettors and disposable tips (10-1000 μL)

  • Multi-channel pipette for efficient processing

  • Microplate reader capable of measuring absorbance at 450 nm

  • Centrifuge capable of 3000 x g

  • Microplate washer or washing bottle

  • Incubator (37°C)

  • Data analysis and graphing software

Methodological recommendation: For consistent results across large sample sets, prepare and aliquot all reagents in advance, maintain consistent incubation times, and develop standard operating procedures with detailed quality control metrics .

What considerations are important when using RPS29 antibodies in different model organisms?

When working across species:

• Epitope conservation analysis:

  • RPS29 sequence is highly conserved across mammals

  • When working with more divergent species, select antibodies targeting the most conserved regions

  • For antibodies with known epitope sequences, perform sequence alignment to predict cross-reactivity

• Model-specific protocol adaptations:

  • Zebrafish studies: Successfully used to model RPS29 mutations in Diamond-Blackfan anemia

  • Insect models: Demonstrated role in metabolic insecticide resistance

  • Cell culture: Various cell lines (HeLa, HepG2, Jurkat, A-431) validated for antibody reactivity

Methodological recommendation: Always validate antibodies in your specific model organism before proceeding with full experiments, even when cross-reactivity is predicted. Consider developing species-specific antibodies for crucial experiments if commercial options show limited reactivity .

How are RPS29 antibodies being used to understand ribosomal protein mutations in human disease?

RPS29 antibodies are instrumental in studying disease mechanisms:

• Diamond-Blackfan anemia research:

  • Whole-exome sequencing identified RPS29 as a novel DBA causative gene

  • Germline mutations (p.I31F and p.I50T) in RPS29 cause haploinsufficiency

  • Antibodies help quantify expression levels of wild-type vs. mutant proteins

  • Used to demonstrate pre-ribosomal RNA processing defects in patients

• Cancer research applications:

  • RPS29 contains a zinc finger domain that can enhance tumor suppressor activity

  • Antibodies help study alterations in expression across cancer types

  • Immunohistochemistry can reveal changes in subcellular localization in tumor samples

• Ribosome biogenesis disorders:

  • RPS29 is essential for rRNA processing and ribosome biogenesis

  • Antibodies help characterize protein-protein interactions in ribosomal assembly complexes

  • Can be used to study stress responses related to ribosomal protein deficiency

Methodological impact: The identification of RPS29 mutations in Diamond-Blackfan anemia has established new research directions for understanding ribosome-related pathologies, with antibodies serving as crucial tools for mechanistic studies and potential therapeutic development .

What are the considerations for using RPS29 antibodies in single-cell analysis techniques?

As single-cell techniques evolve, special considerations apply:

• Signal amplification strategies:

  • RPS29's small size (7 kDa) and relatively low abundance may require signal enhancement

  • Tyramide signal amplification can improve detection in immunofluorescence applications

  • Proximity ligation assays can be used to validate protein-protein interactions at single-cell level

• Antibody validation for single-cell applications:

  • Higher specificity requirements than bulk assays

  • Validate using knockout/knockdown controls at single-cell resolution

  • Compare immunofluorescence patterns with RNA-FISH to confirm correlation

• Multiplexing considerations:

  • Select RPS29 antibodies with minimal cross-reactivity to other ribosomal proteins

  • Choose antibody clones compatible with cyclic immunofluorescence or mass cytometry

  • Develop compatible fixation and permeabilization protocols that preserve epitopes for all targets

Methodological approach: For single-cell protein analysis, consider newer technologies like RT&Tag that can profile RNA at chromatin targets using antibody-directed approaches, allowing for integrated protein-RNA analysis at high resolution .

What is the recommended Western blot protocol for optimal RPS29 detection?

Given RPS29's small size (7 kDa), specialized Western blot protocols are recommended:

• Sample preparation:

  • Lyse cells in RIPA buffer containing protease inhibitor PMSF

  • Use fresh samples when possible or store at -80°C until use

  • Include positive controls (HeLa, HepG2, or Jurkat cell lysates)

• Gel electrophoresis specifications:

  • Use high percentage (15-20%) SDS-PAGE gels for better resolution of small proteins

  • Load adequate protein amount (30-50 μg) for clear detection

  • Include molecular weight markers that resolve in low range (5-20 kDa)

• Transfer and detection protocol:

  • Transfer to nitrocellulose membrane using wet transfer at lower voltage (30V) for longer time (2 hours)

  • Block with 5% skimmed milk for 1 hour at 37°C

  • Incubate with RPS29 primary antibody at 1:1000-1:6000 dilution overnight at 4°C

  • Use horseradish peroxidase-conjugated secondary antibodies at appropriate dilution for 1 hour at 37°C

  • Detect using ECL according to manufacturer's instructions

• Controls and validation:

  • Include loading control (β-actin, tubulin)

  • Expected band size: 7 kDa

  • For validation, pre-incubation with specific blocking peptide should eliminate signal

Methodological recommendation: For consistent results with this small protein, optimize transfer conditions and consider using PVDF membranes with 0.2 μm pore size instead of standard 0.45 μm to prevent protein pass-through during transfer .

What immunohistochemistry protocols provide optimal results with RPS29 antibodies?

For optimal IHC results with RPS29 antibodies:

• Sample preparation guidelines:

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Processing: Standard paraffin embedding

  • Sectioning: 4-5 μm thick sections on positively charged slides

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave)

• Staining protocol:

  • Blocking: 5-10% normal serum from secondary antibody species

  • Primary antibody: Dilute RPS29 antibody 1:50-1:500

  • Incubation: Overnight at 4°C or 1 hour at room temperature

  • Detection system: Compatible polymer/HRP system

  • Counterstain: Hematoxylin for nuclear visualization

• Validated positive control tissues:

  • Mouse brain tissue

  • Human pancreas (demonstrated positive staining at 1:1000 dilution)

Methodological note: When optimizing IHC protocols, create a dilution series (e.g., 1:50, 1:100, 1:200, 1:500) and test both recommended antigen retrieval methods to determine conditions providing optimal signal-to-noise ratio for your specific tissue type .

What protocols are recommended for co-immunoprecipitation experiments with RPS29 antibodies?

For effective co-immunoprecipitation of RPS29 and interacting partners:

• Cell lysis optimization:

  • Use mild lysis buffer to preserve protein-protein interactions

  • Recommended composition: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, with protease inhibitors

  • Avoid harsh detergents like SDS that may disrupt protein interactions

• Pre-clearing protocol:

  • Incubate lysate with Protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

  • Transfer pre-cleared lysate to new tube for immunoprecipitation

• Immunoprecipitation procedure:

  • Add 2-5 μg of RPS29 antibody to 500-1000 μg pre-cleared lysate

  • Incubate overnight at 4°C with gentle rotation

  • Add 30-50 μl Protein A/G beads and incubate 2-4 hours at 4°C

  • Wash beads 3-5 times with cold wash buffer

  • Elute bound proteins by boiling in sample buffer

• Controls and validation:

  • Input sample: 5-10% of lysate used for IP

  • IgG control: Same amount of isotype-matched irrelevant antibody

  • Reverse IP: Use antibody against suspected interaction partner